> For the complete documentation index, see [llms.txt](https://wiki.gen6.life/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://wiki.gen6.life/research/healthcare-and-medical-why-were-not-going-there-yet.md).

# Healthcare & Medical: Why We're Not Going There Yet

### Raw Numbers

**Scale of the problem (the largest of any industry analyzed so far):**

Healthcare data breaches average **$10.22 million per incident** in 2026 — the highest cost of any industry for 14 consecutive years running, a 9.2% increase over the prior year.

**276 million Americans** (81% of the population) had their health data exposed in 2024 — a 64% increase over 2023's record year.

A single stolen medical record sells for **$260–310** on the black market — **10x the value of a stolen credit card**, because medical data doesn't expire or get reissued the way a card number does.

Average breach detection and containment time: **78 days**, during which attackers move freely through the system.

Estimated **$7 billion** lost annually in the US alone from stolen protected health information (PHI).

**This is objectively the largest, most expensive problem of any industry researched to date.** Insurance fraud (only 22% of orgs have AI-fraud tooling) is serious, but healthcare's numbers are an order of magnitude larger.

***

### Market Size and Growth — Where the Picture Gets Complicated

This is the point where honesty matters most: **market size estimates are wildly inconsistent across sources**, which is itself a warning sign.

| Source                      | 2025/2026 Market Size | 2030+ Forecast | CAGR   |
| --------------------------- | --------------------- | -------------- | ------ |
| Mordor Intelligence         | $5.5B (2025)          | $43.37B (2030) | 52.48% |
| Fortune Business Insights   | $2.49B (2025)         | $18.94B (2034) | 24.72% |
| Persistence Market Research | $23.1B (2026)         | $276.2B (2033) | 42.5%  |
| Roots Analysis              | $96M (2026)           | $641M (2035)   | 23.5%  |
| Market.us                   | $18.9B (2026)         | $750B (2033)   | 69.2%  |

**Honest assessment:** A 100x+ spread between sources for the same year ($96M vs. $23.1B) means **market researchers themselves can't agree on what counts as "blockchain healthcare."** Other industries we've researched also showed some spread, but this is the most extreme. It signals a segment still in an early, fragmented phase where even the category definition isn't settled.

***

### Entry Cost — The Critical, Previously Unseen Data Point

This is what sets healthcare apart from every industry analyzed so far, and needs to be stated explicitly:

**A large hospital system spends $15–25 million on core Hospital Information System (HIS) migration alone, plus another $5–8 million on blockchain-ready middleware and staff upskilling.**

Legacy EHR stacks deployed more than a decade ago lack modern API layers, requiring custom connectors or a full system overhaul — a significant budget strain for community hospitals.

The Change Healthcare breach's **$2.3 billion** recovery bill illustrated the capital burden of technology replacement at scale — as a result, many providers schedule blockchain adoption in phased pilots tied to broader EHR renewal cycles, which moderates near-term uptake.

In plain terms: **the buyer isn't purchasing software — they're financing a full infrastructure replacement**, of which a blockchain layer is only one component. This is a fundamentally different sales cycle than what we've seen in other segments (e.g. B2B IP timestamping, where RealSeal is effectively plug-and-play).

***

### The Standards and Technical Barrier — Also Critical

Multiple systematic literature reviews identify **lack of interoperability between heterogeneous healthcare systems** as a major constraint, and note that **compliance with HL7/FHIR standards remains limited in most proposed blockchain solutions.**

A 2026 BMC Medical Informatics systematic review explicitly recommends that the first implementation phase (2026–2027) focus on **standardizing semantic interoperability with HL7 FHIR**, warning of the risk of immutably storing biased or malformed clinical data if this isn't addressed first.

In practical terms: **RealSeal in its current form is not plug-and-play for healthcare data.** Clinical data exchange requires an adapter layer aligned to the HL7 FHIR standard — this is development work, not just a business decision.

***

### Competitive Landscape — Mature and Capital-Intensive

Leading players include IBM Corporation, Microsoft Corporation, Patientory Inc., Guardtime Federal, and Hashed Health. These are large, capital-backed players with existing healthcare relationships already in place. Patientory is already available on the Oracle Healthcare Marketplace; the EY–Sensyne Health–Guardtime collaboration ties healthcare reimbursement directly to treatment outcomes.

This is a **more mature, institutionally entrenched competitive field** than the industrial/agricultural or AI-agent identity markets previously researched, where no dominant standard yet exists.

***

### Comparison Against Previously Researched Industries

| Industry                                   | Problem Scale                  | Entry Cost                        | Competition                           | Immediate Gen6 Fit                          |
| ------------------------------------------ | ------------------------------ | --------------------------------- | ------------------------------------- | ------------------------------------------- |
| B2B IP / contract timestamping             | Medium                         | Low                               | Low                                   | ✅ Yes — existing RealSeal                   |
| AI agent identity                          | Large, forming now             | Low                               | Low, no dominant standard             | ✅ Yes — human/machine distinction is native |
| Insurance fraud (deepfake)                 | Large                          | Medium                            | Medium                                | ✅ Yes — RealSeal timestamping               |
| Industrial / agriculture (ThermoSeal-type) | Large ($1B+)                   | Medium                            | High (IBM, SAP, VeChain)              | ⚠️ Yes, at pilot scale                      |
| Pharmaceutical (prior research)            | Large                          | High (GS1/EPCIS)                  | High                                  | ⚠️ Long-term play                           |
| **Healthcare / Medical (this research)**   | **Largest** ($10.22M/incident) | **Highest** ($15–33M/institution) | **High** (IBM, Microsoft, Patientory) | ❌ **Not immediate**                         |

***

### Honest Verdict

**Healthcare is NOT a good immediate target for Gen6 — not because the problem isn't real, but for purely structural reasons.** The problem is the largest and most expensive of any industry researched. The case against it as a near-term priority rests on four points:

1. **Entry cost ($15–33M per institution) is orders of magnitude beyond what an early-stage project with 150+ validators and $1.5M raised can realistically target on its own.** This isn't a "buy a license" decision for a buyer — it's a full infrastructure project where Gen6 could only be a subcontracted component.
2. **HL7/FHIR alignment is development work, not a business decision.** RealSeal in its current form isn't directly consumable in a clinical workflow, unlike B2B IP timestamping or AI agent identity, where the existing infrastructure applies immediately.
3. **Competitors (IBM, Microsoft, Patientory) are already embedded**, with existing hospital relationships and Oracle/EY-level partnerships. This is not a "no dominant standard, agile entry window" market like AI agent identity.
4. **The 100x+ spread in market size estimates** signals that the category itself isn't well-defined yet, making it hard to position precisely in such a volatile-definition space.

***

### If Healthcare Remains a Long-Term Strategic Goal

Rather than targeting the full EHR / clinical data layer first, a narrower, RealSeal-compatible entry point would apply the existing infrastructure immediately, without new development:

* **Medical device / implant authenticity verification** — not clinical data, but physical product provenance, closer to the industrial/agricultural ThermoSeal pattern than to full EHR integration
* **Medical license / credential verification** — cryptographically proving a physician's qualification or license is document-signing, not clinical data exchange, so RealSeal handles it natively

These aren't "healthcare data management" projects — they're **healthcare-specific applications of the existing B2B document-proof use case**, where Gen6's strengths (RealSeal, low entry cost) apply without the structural barriers above (HL7/FHIR, $15–33M entry cost).

***

**One-line summary:** Healthcare is the largest dollar-value problem researched to date, but the entry barrier is too high relative to Gen6's current scale and maturity to be an immediate target — B2B IP timestamping and AI agent identity remain the stronger, immediately addressable directions.